- Conditions
- Type 1 Diabetes
- Interventions
- PassPort(R) Transdermal Insulin Delivery System
- Other
- Lead sponsor
- Altea Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- 387 Technology Circle, NW, Suite 100, Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 3,443
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- PF-03732010
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Venous Thrombosis, Atrial Fibrillation, Myocardial Infarction
- Interventions
- Genomics
- Device
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Solid Tumors (Phase 1), RAS Mutation
- Interventions
- AN9025 oral capsule
- Drug
- Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Tampa, Florida • Houston, Texas
- Conditions
- HEAD & NECK Cancer
- Interventions
- ribavirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Disorders With Hyperactivity
- Interventions
- Pharmacogenomics report
- Diagnostic Test
- Lead sponsor
- Clinical and Translational Genome Research Institute, Inc.
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
- Conditions
- Healthy Volunteers
- Interventions
- KINE-101, Placebo
- Drug
- Lead sponsor
- Kine Sciences Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- sirolimus, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- MItochondrial Myopathies
- Interventions
- Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg, Placebo capsules, omaveloxolone capsules, 20 mg, omaveloxolone capsules, 40 mg, omaveloxolone capsules, 80 mg, omaveloxolone capsules, 160 mg
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more
- Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS)
- Interventions
- KYN-5356 low dose, Placebo, KYN-5356 Medium Dose, KYN-5356 High Dose
- Drug · Other
- Lead sponsor
- Kynexis B.V.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 12 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Evolocumab, Placebo
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- End Stage Renal Disease
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Advanced Cancer
- Interventions
- RDEA119
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Buffalo, New York
- Conditions
- Parkinson's Disease
- Interventions
- pramipexole
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Obesity and Cardiovascular Risk
- Interventions
- Oral BGE-102, Oral Placebo Matching BGE-102
- Drug
- Lead sponsor
- BioAge Labs, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more
- Conditions
- Healthy, Renal Dysfunction
- Interventions
- Danicopan
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Healthy Subjects
- Interventions
- E2027, E2027 matched placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
- Interventions
- AZD8701, Durvalumab
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
- Conditions
- Advanced Melanoma and Normal or Impaired, Advanced Melanoma
- Interventions
- AB821
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Major Depressive Disorder
- Interventions
- CYB003, Psychotherapy, Placebo, Psychological Support
- Drug · Behavioral
- Lead sponsor
- Cybin IRL Limited
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
- Conditions
- Healthy Participants
- Interventions
- BMS-986421, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ALLO-715, ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat
- Genetic · Biological · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Duarte, California • Palo Alto, California + 8 more
- Conditions
- Obesity
- Interventions
- ERX1000, Placebo
- Drug
- Lead sponsor
- ERX Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases, Exophthalmos, Orbital Diseases, Goiter, Thyroid Diseases, Endocrine System Diseases, Hyperthyroidism, Autoimmune Diseases, Immune System Diseases, Graves Ophthalmopathy, Proptosis
- Interventions
- ETHY-001, Placebo
- Drug · Other
- Lead sponsor
- Ethyreal Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Orland Park, Illinois • Las Vegas, Nevada • Wilmington, North Carolina